Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells
Background/Aims: Drug resistance is the main difficulty for the current treatment for osteosarcoma. Cluster of differentiation 44 (CD44) is a receptor for hyaluronic acid (HA) and HA-binding has been proven to participate in various biological tumor activities, including tumor progression, metastasi...
Main Authors: | Zheng Xiao, Jia Wan, Ayub Abdulle Nur, Pencheng Dou, Henry Mankin, Tang Liu, Zhengxiao Ouyang |
---|---|
Format: | Article |
Language: | English |
Published: |
Cell Physiol Biochem Press GmbH & Co KG
2018-11-01
|
Series: | Cellular Physiology and Biochemistry |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/495714 |
Similar Items
-
CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells
by: Tang Liu, et al.
Published: (2018-04-01) -
Applications of CRISPR/Cas9 in the research of malignant musculoskeletal tumors
by: Wei Liu, et al.
Published: (2021-02-01) -
Systematic screening for potential therapeutic targets in osteosarcoma through a kinome-wide CRISPR-Cas9 library
by: Yuanzhong Wu, et al.
Published: (2020-08-01) -
Precise and Rapid Validation of Candidate Gene by Allele Specific Knockout With CRISPR/Cas9 in Wild Mice
by: Tianzhu Chao, et al.
Published: (2019-02-01) -
Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems
by: Fei Zhang, et al.
Published: (2019-06-01)